U.S. market Closed. Opens in 21 hours 27 minutes

ZURA | Zura Bio Limited Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.2100 - 1.3400
52 Week Range 1.0700 - 6.35
Beta 0.49
Implied Volatility 321.86%
IV Rank 41.80%
Day's Volume 201,164
Average Volume 350,970
Shares Outstanding 68,375,000
Market Cap 86,494,375
Sector Healthcare
Industry Biotechnology
IPO Date 2023-03-21
Valuation
Profitability
Growth
Health
P/E Ratio -2.11
Forward P/E Ratio N/A
EPS -0.60
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 14
Country USA
Website ZURA
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
*Chart delayed
Analyzing fundamentals for ZURA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ZURA Fundamentals page.

Watching at ZURA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ZURA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙